<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05058014</url>
  </required_header>
  <id_info>
    <org_study_id>SIB1802</org_study_id>
    <secondary_id>IRB00157231</secondary_id>
    <nct_id>NCT05058014</nct_id>
  </id_info>
  <brief_title>Skeletal Metastasis Registry</brief_title>
  <official_title>The International Skeletal Metastasis Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Murtha Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Defense Health Programs with the U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, observational study designed to contribute data from patients with&#xD;
      symptomatic metastatic bone disease treated at Sibley Memorial Hospital and Johns Hopkins&#xD;
      Medicine to an international registry hosted by the Swedish Regional Cancer Centrum in&#xD;
      Stockholm, Sweden. This protocol supports a worldwide effort to collect and store information&#xD;
      from patients treated for symptomatic bone metastases within the International Skeletal&#xD;
      Metastasis Registry (ISMR)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The registry is designed to update a suite of clinical decision-support tools designed for&#xD;
      use when treating patients with metastatic bone disease. The models estimate the likelihood&#xD;
      of survival at 1, 3, 6, 12, 18, and 24 months post surgery, which in turn, may be used for&#xD;
      surgical decision-making.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2018</start_date>
  <completion_date type="Anticipated">August 16, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 Months post surgery</time_frame>
    <description>OS (in months) calculated from the date of intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reoperation or retreatment for any reason</measure>
    <time_frame>Up to 24 24 months post surgery</time_frame>
    <description>Number of participants with reoperation or retreatment for any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reoperation or retreatment for any reason</measure>
    <time_frame>Up to 24 months post surgery</time_frame>
    <description>Timing of reoperation calculated from the date of intervention.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Bone Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic bone disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients, age 22 or older&#xD;
&#xD;
          -  Biopsy-proven or clinically-obvious metastatic bone disease&#xD;
&#xD;
          -  Symptomatic bone lesion requiring intervention o Including, not limited to,&#xD;
             radiotherapy, cryotherapy, radiofrequency ablation, operative fixation, prosthetic&#xD;
             replacement, amputation, or any combination of the above.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Forsberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacqueline Quivers</last_name>
    <phone>202-243-2294</phone>
    <email>jquiver1@jhmi.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kelly Carr</last_name>
    <phone>202-660-7021</phone>
    <email>kcarr20@jhmi.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sibley Memorial Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon Forsberg</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 6, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 27, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Biopsy-proven or clinically-obvious metastatic bone disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

